Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Banerjee was surprised the patient got benefit from pelvic radiation, but at Royal Marsden she has seen radiotherapy work less well in LGSOC than in high-grade ovarian cancer. She would consider it for focal lesions when options are limited, while weighing toxicity and trial access.

Related Insights

The traditional definition of platinum-resistant ovarian cancer based on a six-month recurrence interval is becoming less rigid. Clinicians recognize this timeframe can be an arbitrary surrogate for tumor biology, influenced by imaging schedules. The paradigm is shifting, especially post-PARP inhibitor therapy, where the value of re-challenging with platinum is being reconsidered despite shorter intervals.

Following high response rates to systemic therapies like EV Pembro, using radiation for bladder preservation is now questioned. It may constitute overtreatment by radiating a now cancer-free organ, while providing no benefit for the systemic micrometastases that are the primary driver of mortality.

Clinicians are concerned about the overuse of Stereotactic Body Radiation Therapy (SBRT) for oligoprogressive disease, a practice dubbed 'Pokemon' (gotta catch 'em all). This approach of sequentially radiating new lesions can delay the start of more effective systemic therapies and is not considered a standard of care.

For ovarian cancer patients with limited, or oligometastatic, disease, stereotactic body radiation therapy (SBRT) is a valuable and low-toxicity option. A key advantage is that it can be administered to symptomatic areas without delaying or interrupting the patient's crucial systemic therapy regimen.

Using radiation as a consolidation therapy after chemo has a significant downside. It damages local tissue, limiting future surgical options and often precluding a neobladder reconstruction—a major quality-of-life factor for patients who may relapse later and require surgery.

Even patients with "low-risk" advanced ovarian cancer face an 85% chance of recurrence. This high baseline risk justifies aggressive upfront combination therapies, like adding bevacizumab, to maximize the potential for a curative outcome without leaving any options off the table.

Contrary to broad application, data suggests radiation's main benefit in endometrial cancer is for patients in the non-specific molecular profile (NSMP) group. This molecularly-defined approach refines adjuvant treatment decisions, moving away from a one-size-fits-all strategy based on stage alone.

Unlike many cancers, younger patients (in their 20s-30s) with low-grade serous ovarian cancer have a worse prognosis than older patients. This is because they are less likely to carry a KRAS mutation, making them less responsive to highly effective targeted therapies.

Clinical experience suggests that CSCC recurring within or at the edge of a prior radiation field tends to exhibit more aggressive biological behavior. This context is a critical factor when assessing risk and deciding on subsequent treatment, such as adjuvant systemic therapy, even if other features seem borderline.

The classification of platinum-resistant ovarian cancer is evolving. Clinicians argue it's not a rigid biological state but often a function of imaging timing. They recognize platinum can still be effective in this population, challenging the strict definition used for trial eligibility and treatment decisions.